WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H319623
CAS#: 476436-68-7
Description: Naveglitazar, also known as LY 519818, LY 9818, is a peroxisome proliferator-activated receptor (PPAR) modulator, had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, no recent development for this indication has been reported.
Hodoodo Cat#: H319623
Name: Naveglitazar
CAS#: 476436-68-7
Chemical Formula: C25H26O6
Exact Mass: 422.17
Molecular Weight: 422.477
Elemental Analysis: C, 71.07; H, 6.20; O, 22.72
Synonym: LY519818; LY-519818; LY 519818; LY-9818; LY9818; LY 9818; CCRIS 9448; Naveglitazar.
IUPAC/Chemical Name: (S)-2-methoxy-3-(4-(3-(4-phenoxyphenoxy)propoxy)phenyl)propanoic acid
InChi Key: OKJHGOPITGTTIM-DEOSSOPVSA-N
InChi Code: InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1
SMILES Code: O=C(O)[C@@H](OC)CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 422.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Tseng CH, Tseng FH. Peroxisome proliferator-activated receptor agonists and
bladder cancer: lessons from animal studies. J Environ Sci Health C Environ
Carcinog Ecotoxicol Rev. 2012;30(4):368-402. doi: 10.1080/10590501.2012.735519.
Review. PubMed PMID: 23167631.
2: Long GG, Reynolds VL, Dochterman LW, Ryan TE. Neoplastic and non-neoplastic
changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR
alpha/gamma agonist. Toxicol Pathol. 2009 Oct;37(6):741-53. doi:
10.1177/0192623309343775. Epub 2009 Aug 21. PubMed PMID: 19700659.
3: Ahlawat P, Srinivas NR. Allometric prediction of the human pharmacokinetic
parameters for naveglitazar. Eur J Drug Metab Pharmacokinet. 2008
Jul-Sep;33(3):187-90. PubMed PMID: 19007045.
4: Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR.
Urothelial carcinogenesis in the urinary bladder of rats treated with
naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for
urolithiasis as an inciting event. Toxicol Pathol. 2008 Feb;36(2):218-31. doi:
10.1177/0192623307311757. PubMed PMID: 18474944.
5: Yi P, Hadden CE, Annes WF, Jackson DA, Peterson BC, Gillespie TA, Johnson JT.
The disposition and metabolism of naveglitazar, a peroxisome
proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice,
rats, and monkeys. Drug Metab Dispos. 2007 Jan;35(1):51-61. Epub 2006 Sep 29.
PubMed PMID: 17012539.
